Imunon (IMNN) General Counsel reports stock grant and 920-share sale

Rhea-AI Filing Summary

Imunon, Inc.'s General Counsel and Corporate Secretary, Susan Eylward, reported two recent transactions in the company's common stock. On July 2, 2026, she acquired 920 shares at $1.91 per share as a stock grant in lieu of a portion of her base salary. On July 6, 2026, she executed an open-market sale of 920 shares at $1.88 per share. After these transactions, she directly holds 2,896 shares of Imunon common stock.

Insider Trade Summary

Net Seller: 920 shares ($1,730)

Net Sell 2 txns

Insider Eylward Susan

Role General Counsel and Corp Sec

Sold 920 shs ($2K)

Type	Security	Shares	Price	Value
Sale	Common Stock	920	$1.88	$2K
Grant/Award	Common Stock	920	$1.91	$2K

Holdings After Transaction: Common Stock — 2,896 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock grant: 920 shares at $1.91 Open-market sale: 920 shares at $1.88 Shares after transactions: 2,896 shares +1 more

4 metrics

Stock grant 920 shares at $1.91 Common stock granted in lieu of cash salary on July 2, 2026

Open-market sale 920 shares at $1.88 Common stock sale on July 6, 2026

Shares after transactions 2,896 shares Direct holdings of Imunon common stock following reported trades

Net share change -920 shares Net effect of grant and sale per transaction summary

Key Terms

open-market sale, grant/award acquisition, in lieu of cash, Form 4

4 terms

open-market sale financial

"reported as an open-market sale of 920 shares at $1.88"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

grant/award acquisition financial

"classified as a grant/award acquisition of 920 common shares"

in lieu of cash financial

"stock granted in lieu of cash for portion of base salary"

Form 4 regulatory

"these moves were disclosed on a Form 4 insider trading report"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/07/2026 - 04:58 PM Accepted by SEC EDGAR 07/07/2026 - 04:58 PM Learn about SEC filing dates

FAQ

What insider transactions did Imunon (IMNN) report for Susan Eylward?

Imunon reported that General Counsel Susan Eylward received a grant of 920 common shares and later sold 920 shares in an open-market transaction. These moves were disclosed on a Form 4 insider trading report.

How many Imunon (IMNN) shares did Susan Eylward sell and at what price?

Susan Eylward sold 920 shares of Imunon common stock at $1.88 per share. This was reported as an open-market or private sale transaction under code “S” on the Form 4 filing.

What stock grant did Susan Eylward receive from Imunon (IMNN)?

She received a grant of 920 Imunon common shares at $1.91 per share. A footnote explains this stock was granted in lieu of cash for a portion of her base salary, reflecting compensation in equity.

How many Imunon (IMNN) shares does Susan Eylward own after these transactions?

Following the reported grant and subsequent sale, Susan Eylward directly owns 2,896 shares of Imunon common stock. This post-transaction holding amount is disclosed in the Form 4 for each transaction line.

Is Susan Eylward’s Imunon (IMNN) transaction a buy or a sell?

The Form 4 shows a mix of actions: an acquisition via a stock grant and a separate open-market sale. Overall, the net result is a disposition of 920 shares relative to her prior position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Eylward Susan

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Corp Sec

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/02/2026		A		920(1)	A	$1.91	3,816	D
Common Stock	07/06/2026		S		920	D	$1.88	2,896	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for portion of base salary

	/s/ Susan Eylward	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)